AMLXClinical Trials•businesswire•
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
Sentiment:Negative (-70)
Summary
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 27, 2025 by businesswire